NASDAQ:INCYIncyte Stock Price, Forecast & News

$99.37

+0.69 (+0.70 %)

(As of 05/26/2020 04:00 PM ET)

Add

Compare

Today's Range

$97.45

Now: $99.37▼

$99.80

50-Day Range

$78.59

MA: $95.89▼

$103.48

52-Week Range

$62.48

Now: $99.37▼

$104.81

Volume1.32 million shs

Average Volume1.43 million shs

Market Capitalization$21.60 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.06

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Incyte has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 12 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $99.42, Incyte has a potential upside of 0.1% from its current price of $99.37.
Amount of Analyst Coverage
Incyte has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.1 Community Rank

Outperform Votes
Incyte has received 1,137 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Incyte has received 709 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Incyte has received 61.59% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote “Outperform” if you believe INCY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Incyte does not currently pay a dividend.
Dividend Growth
Incyte does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,036,107.00 in company stock.
Percentage Held by Insiders
Only 17.10% of the stock of Incyte is held by insiders.
Percentage Held by Institutions
91.34% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Incyte are expected to grow in the coming year, from ($1.29) to $2.84 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Incyte is -56.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Incyte is -56.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Incyte has a P/B Ratio of 11.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.40 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Commercial physical research

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:INCY

Previous Symbol

CUSIP45337C10

CIK879169

Webwww.incyte.com

Phone302-498-6700

Debt

Debt-to-Equity Ratio0.02

Current Ratio3.41

Quick Ratio3.38

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.16 billion

Price / Sales10.01

Cash Flow$2.50 per share

Price / Cash Flow39.71

Book Value$8.91 per share

Price / Book11.15

Profitability

EPS (Most Recent Fiscal Year)$2.23

Net Income$446.91 million

Net Margins-16.87%

Return on Equity-12.81%

Return on Assets-9.55%

Miscellaneous

Employees1,456

Outstanding Shares217,370,000

Market Cap$21.60 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

Incyte (NASDAQ:INCY) Frequently Asked Questions

How has Incyte's stock been impacted by COVID-19 (Coronavirus)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INCY shares have increased by 38.2% and is now trading at $99.37. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Incyte?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 9 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Incyte.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Incyte.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) released its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported ($2.86) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.31 by $3.17. The biopharmaceutical company had revenue of $568.51 million for the quarter, compared to analysts' expectations of $553.24 million. Incyte had a negative return on equity of 12.81% and a negative net margin of 16.87%. The company's quarterly revenue was up 14.2% on a year-over-year basis. During the same period last year, the firm earned $0.62 earnings per share. View Incyte's earnings history.

What price target have analysts set for INCY?

21 analysts have issued 1 year price targets for Incyte's stock. Their forecasts range from $79.00 to $121.00. On average, they expect Incyte's stock price to reach $99.42 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View analysts' price targets for Incyte.

Has Incyte been receiving favorable news coverage?

Press coverage about INCY stock has been trending somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Incyte earned a coverage optimism score of -1.1 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutIncyte.

Are investors shorting Incyte?

Incyte saw a increase in short interest in April. As of April 30th, there was short interest totaling 7,230,000 shares, an increase of 17.6% from the April 15th total of 6,150,000 shares. Based on an average trading volume of 2,020,000 shares, the short-interest ratio is presently 3.6 days. Currently, 3.4% of the shares of the company are short sold. View Incyte's Current Options Chain.

Who are some of Incyte's key competitors?

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Micron Technology (MU), Array Biopharma (ARRY) and Celgene (CELG).

Who are Incyte's key executives?

Incyte's management team includes the following people:

Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)
Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel
Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)
Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)
Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48)

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.06%), Capital International Investors (4.36%), State Street Corp (3.85%), Invesco Ltd. (1.52%), Geode Capital Management LLC (1.38%) and AQR Capital Management LLC (0.99%). Company insiders that own Incyte stock include Barry P Flannelly, Dashyant Dhanak, Jean Jacques Bienaime, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View institutional ownership trends for Incyte.

Which major investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., APG Asset Management N.V., APG Asset Management N.V., Nicholas Investment Partners LP, Two Sigma Investments LP, Alliancebernstein L.P., Squarepoint Ops LLC, and Invesco Ltd.. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Dashyant Dhanak, Jean Jacques Bienaime, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon, and Yao Wenqing. View insider buying and selling activity for Incyte.

Which major investors are buying Incyte stock?

INCY stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, Camber Capital Management LP, NWQ Investment Management Company LLC, First Trust Advisors LP, Eaton Vance Management, Sector Gamma AS, and PGGM Investments. View insider buying and selling activity for Incyte.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $99.37.

How big of a company is Incyte?

Incyte has a market capitalization of $21.60 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff